Ambit Biosciences
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.
Afraxis, Inc. is a contract research organization based in San Diego, California, that specializes in preclinical efficacy evaluations, including both in vivo and in vitro methods, as well as neurotoxicity evaluations and structure-efficacy relationship-driven medicinal chemistry. The company utilizes its enhanced spine profiling technology to deliver rapid and detailed insights into synaptic networks from various tissue preparations. This technology includes specialized neuron labeling, high-resolution imaging, and advanced statistical methods for interpreting large data sets. Afraxis also provides in vivo high-content analysis services, encompassing live cell imaging and N-dimensional analysis. In addition to these services, the company is involved in drug discovery, focusing on developing treatments for central nervous system disorders such as schizophrenia, Alzheimer's disease, Fragile X syndrome, and autism spectrum disorders. Founded in 2007, Afraxis is dedicated to advancing research in neuropharmacology and assessing potential adverse cognitive impacts related to drug development.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.